Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer-Reference-Cited by-同舟云学术

Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer

Published:2023-03 Issue: Volume:189 Page:106703
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Guan Xiaoqing,Yang Jing,Wang Weiyi,Zhao Bing,Hu Shiyu,Yu Dehua,Yuan Li,Shi Yunfu,Xu Jingli,Dong Jinyun,Wang Jinxin,Cheng Xiang-Dong,Qin Jiang-Jiang

Publisher

Elsevier BV

Subject

Pharmacology

Reference45 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. Antibody-targeted drugs and drug resistance--challenges and solutions;Shefet-Carasso;Drug Resist Updat,2015

3. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review;Qin;J. Exp. Clin. Cancer Res,2019

4. Biological hallmarks and emerging strategies to target STAT3 signaling in multiple myeloma;Zhou;Cells,2022

5. Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity;Moreira;J. Clin. Invest,2021

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024);Chinese Chemical Letters;2024-09

2. TTI-101 targets STAT3/c-Myc signaling pathway to suppress cervical cancer progression: an integrated experimental and computational analysis;Cancer Cell International;2024-08-12

3. Tumor microenvironment characteristics of lipid metabolism reprogramming related to ferroptosis and EndMT influencing prognosis in gastric cancer;International Immunopharmacology;2024-08

4. Interleukin-6 serves as a critical factor in various cancer progression and therapy;Medical Oncology;2024-06-20

5. Targeting IL-6/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC;Cancer Letters;2024-04